A secondary analysis of the phase 3 CARDIOTTRansform trial presented at the 2026 ESC Congress found that the antisense oligonucleotide eplontersen improved outcomes in transthyretin amyloid cardiomyopathy patients not taking transthyretin stabilizers at baseline, but showed no s…
Eplontersen shows benefit in transthyretin amyloid cardiomyopathy only without stabilizers
A secondary analysis of the phase 3 CARDIOTTRansform trial presented at the 2026 ESC Congress found that the antisense oligonucleotide eplontersen improved outcomes in transthyretin amyloid cardiomyopathy patients not taking transthyretin stabilizers at baseline, but showed no such benefit in those already on stabilizers.
Amyloid cardiomyopathy · Wikimedia — licence per file · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.